Portfolio launch readiness
7 products in market or inside their launch window. Status rolls up automatically from the five readiness pillars — Market Access & Evidence and Regulatory, Supply & Product block a launch, the other three are advisory.
Product
Country
Showing the whole portfolio
Launches tracked
53
7 products
Every product and country in the programme.
On track
44
83%
Click to see these launches
At risk
8
15%
A pillar has gone amber. Launch is not blocked.
Click to see these launches
What is being done to de-risk →
Off track
1
2%
Market Access or Regulatory is red. Launch is blocked until it clears.
Click to see these launches
What is being done to recover →
Revenue at risk
$65M
4% of the $1.5B year-one forecast is exposed
Blocked $26M
At risk $39M
Secure $1.5B
$26M sits behind launches that are blocked today. A further $39M sits behind launches carrying an open amber pillar.
Basis: year-one revenue per launch = analyst peak-sales potential per asset x 12% first-year uptake x market share. Exposure scales with the weighted readiness gap (min. 50% on an off-track launch, 20% on an at-risk launch).
Top 5 contributors
Zasocitinib — 2027
$26M
Off track · launches in 286 days · $52M forecast
Zasocitinib — 2027
$12M
At risk · launches in 268 days · $62M forecast
Oveporexton — 2026
$8M
At risk · launches in 85 days · $40M forecast
Zasocitinib — 2027
$7M
At risk · launches in 329 days · $36M forecast
Where your attention is needed
1 launch is blocked by a red Market Access or Regulatory pillar. Each one needs a named decision this week.
Blocking pillars first, then the nearest launch date
Critical
Zasocitinib — 2027 — Germany · Market Access & Evidence
Launches in 286 days
G-BA / IQWiG issued a negative preliminary recommendation on the submitted dossier. Launch is blocked until this clears.
View launch
Why this matters
Medium
Rusfertide — 2026 — Germany · Market Access & Evidence
Launches in 72 days
G-BA / IQWiG has not yet scheduled a committee slot. The review window is slipping.
View launch
Why this matters
Medium
Oveporexton — 2026 — Germany · Market Access & Evidence
Launches in 85 days
G-BA / IQWiG has not yet scheduled a committee slot. The review window is slipping.
View launch
Why this matters
Medium
Mezagitamab — IgAN — United Kingdom · Market Access & Evidence
Launches in 265 days
NICE has not yet scheduled a committee slot. The review window is slipping.
View launch
Why this matters
Medium
Zasocitinib — 2027 — Japan · Market Access & Evidence
Launches in 268 days
Chuikyo has not yet scheduled a committee slot. The review window is slipping.
View launch
Why this matters
Products
Select a product to see its countries